Ambroxol hydrochloride spray (Luo Runchang®) in the treatment of acute respiratory infectious diseases: A prospective, multicenter, open label, randomized controlled study
Author:
Cheng Lu1, Liu Min2, Wang Rong3, Cao Sufen4, Li Rui5, Su Bo2, Wei Hongyan3, Yang Haijuan4, Hou Lingyun5, Ge Chunyu2, Han Yuling1, Yang Tianrui6
Affiliation:
1. Jinan Children's Hospital 2. Jinan City People's Hospital 3. People's Hospital of Cangzhou 4. Langfang People’s Hospital 5. Linyi People's Hospital 6. The University of Texas at Tyler
Abstract
Abstract
Purpose Cough and sputum are the most common clinical symptoms of acute respiratory tract infection. Ambroxol is a mucolytic expectorant commonly used in clinical practice. This study aims to evaluate the efficacy, safety, and compliance of ambroxol hydrochloride spray (Luo Runchang ®) for the treatment of acute respiratory tract diseases in children.Methods In this multicenter, open-labeled, randomized controlled study, 154 subjects were randomized and included in the analysis. The experimental group received ambroxol hydrochloride sprays, and the control group received ambroxol hydrochloride oral solutions. The primary endpoint was the change in cough symptom scores from baseline. Secondary endpoints include changes in cough severity score, quality of life, adherence, and adverse events.Results The mean change of total cough symptom score of the spray group at the end of treatment was − 4.7(1.54) compared to -4.2(1.62) in the solution group (P = 0.0005). The mean change of cough severity score was − 5.7(2.09) in the spray group compared to -5.2(2.04) in the solution group (P = 0.012). Quality of life scores significantly improved in the spray group (P < 0.0001). Medication adherence markers were significantly better in the spray group (P < 0.0001). The incidence of adverse events in the experimental group (1.33%) was lower than that in the control group (6.33%), but the difference between the groups was not statistically significant.Conclusion Ambroxol hydrochloride spray significantly improved cough symptom score, cough severity score, and quality of life score compared to ambroxol hydrochloride oral solution.
Publisher
Research Square Platform LLC
Reference24 articles.
1. J. P. Mizgerd, “Lung infection–a public health priority.,” PLoS Med., vol. 3, no. 2, p. e76, Feb. 2006, doi: 10.1371/journal.pmed.0030076. 2. C. J. L. Murray et al., “Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition.,” Lancet, vol. 386, no. 10009, pp. 2145–2191, Nov. 2015, doi: 10.1016/S0140-6736(15)61340-X. 3. “Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals;Liu L;Lancet,2016 4. A. D. Hay, J. Heron, A. Ness, and ALSPAC study team, “The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study.,” Fam. Pract., vol. 22, no. 4, pp. 367–374, Aug. 2005, doi: 10.1093/fampra/cmi035. 5. J. M. Marchant, P. A. Newcombe, E. F. Juniper, J. K. Sheffield, S. L. Stathis, and A. B. Chang, “What is the burden of chronic cough for families?,” Chest, vol. 134, no. 2, pp. 303–309, Aug. 2008, doi: 10.1378/chest.07-2236.
|
|